Avalon GloboCare Corp (NASDAQ:ALBT) revealed that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.
The Freehold, New Jersey-based biotechnology company is enabling the development and commercialization of companion diagnostics and novel therapeutic targets for leukemia patients.
In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal.
Fusion genes are important genetic abnormalities in leukemia, according to the company. Using advanced gene sequencing technology, called Whole Transcriptome Sequencing (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets, said the company.
“Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis,” Avalon GloboCare CEO David Jin said in a statement.
“Avalon is applying the bioinformatics from the fusion gene map with the goal of accelerating the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients,” he added.
Jin noted that the first diagnostic prototype is expected to enter clinical study and the regulatory filing stage during the third quarter of 2023.
“The fusion gene map technology also provides an unprecedented opportunity to identify and validate fusion gene products as potential novel therapeutic targets,” noted Jin. “Additionally, this gives us an opportunity to expand Avalon’s R&D pipeline and intellectual property portfolio.”
Avalon develops innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive